Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Mineralocorticoid-receptor blockade, hypertension and heart failure

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout


  1. Pitt B et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709–717

    Article  CAS  Google Scholar 

  2. Pitt B et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321

    Article  CAS  Google Scholar 

  3. Pitt B et al. (2003) Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108: 1831–1838

    Article  CAS  Google Scholar 

  4. Rocha R et al. (2002) Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143: 4828–4836

    Article  CAS  Google Scholar 

  5. Juurlink D et al. (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543–551

    Article  CAS  Google Scholar 

  6. Bozkurt B et al. (2003) Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 41: 211–214

    Article  CAS  Google Scholar 

  7. Levy D et al. (2004) Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 89: 2736–2740

    Article  CAS  Google Scholar 

  8. Funder JW et al. (1988) Mineralocorticoid action: target-tissue specificity is enzyme, not receptor, mediated. Science 242: 583–585

    Article  CAS  Google Scholar 

  9. Funder JW and Myles K (1996) Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 137: 5264–5268

    Article  CAS  Google Scholar 

  10. Funder JW (2004) Is aldosterone bad for the heart? Trends Endocrinol Metab 15: 139–142

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to John W Funder.

Ethics declarations

Competing interests

Dr Funder is a consultant for Eli Lilly, Merck, Pfizer, cBio, Exelisis, GNF and Kalypsis, and holds research grants from Merck and Pfizer.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Funder, J. Mineralocorticoid-receptor blockade, hypertension and heart failure. Nat Rev Endocrinol 1, 4–5 (2005).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing